Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
暂无分享,去创建一个
[1] A. Colao,et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. , 1997, The Journal of clinical endocrinology and metabolism.
[2] A. Barlier,et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. , 1996, European journal of endocrinology.
[3] M. Vance,et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. , 1996, The Journal of clinical endocrinology and metabolism.
[4] J. Donckier,et al. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. , 1996, European journal of endocrinology.
[5] C. Nappi,et al. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. , 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[6] A. Colao,et al. Clinical management of prolactinomas: A ten-year experience , 1992, Medical oncology and tumor pharmacotherapy.
[7] A. Paracchi,et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. , 1992, Acta endocrinologica.